- Home
- TCOM vs RGC Comparison
TCOM vs RGC Comparison
Compare TCOM & RGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCOM
- RGC
- Stock Information
- Founded
- TCOM 1999
- RGC 2014
- Country
- TCOM Singapore
- RGC Hong Kong
- Employees
- TCOM N/A
- RGC N/A
- Industry
- TCOM Hotels/Resorts
- RGC Medicinal Chemicals and Botanical Products
- Sector
- TCOM Consumer Discretionary
- RGC Health Care
- Exchange
- TCOM Nasdaq
- RGC Nasdaq
- Market Cap
- TCOM 40.2B
- RGC 38.6B
- IPO Year
- TCOM 2003
- RGC 2021
- Fundamental
- Price
- TCOM $63.09
- RGC $13.70
- Analyst Decision
- TCOM Strong Buy
- RGC
- Analyst Count
- TCOM 10
- RGC 0
- Target Price
- TCOM $77.88
- RGC N/A
- AVG Volume (30 Days)
- TCOM 2.8M
- RGC 2.8M
- Earning Date
- TCOM 08-25-2025
- RGC 06-30-2025
- Dividend Yield
- TCOM 0.48%
- RGC N/A
- EPS Growth
- TCOM 51.63
- RGC N/A
- EPS
- TCOM 3.38
- RGC N/A
- Revenue
- TCOM $7,609,591,404.00
- RGC N/A
- Revenue This Year
- TCOM $17.32
- RGC N/A
- Revenue Next Year
- TCOM $14.47
- RGC N/A
- P/E Ratio
- TCOM $18.27
- RGC N/A
- Revenue Growth
- TCOM 16.95
- RGC N/A
- 52 Week Low
- TCOM $38.23
- RGC $0.08
- 52 Week High
- TCOM $77.18
- RGC $83.60
- Technical
- Relative Strength Index (RSI)
- TCOM 60.90
- RGC 44.61
- Support Level
- TCOM $60.20
- RGC $13.54
- Resistance Level
- TCOM $62.74
- RGC $30.00
- Average True Range (ATR)
- TCOM 1.04
- RGC 4.97
- MACD
- TCOM 0.50
- RGC -1.47
- Stochastic Oscillator
- TCOM 99.34
- RGC 20.91
About TCOM Trip.com Group Limited
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 79% of sales from accommodation reservations and transportation ticketing in 2024. The rest of revenue comes from package tours and corporate travel. Before the pandemic in 2019, the company generated 25% of revenue from international travel, which is important to its margin expansion. Most of sales come from its domestic platform, but the company is expanding its overseas business. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Tongcheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.